Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

Rhea-AI Summary

Mirum Pharmaceuticals (MIRM) will present at the virtual J.P. Morgan Healthcare Conference from January 10-13, 2022. CEO Chris Peetz will share insights on the company’s strategy and updates on LIVMARLI™ (maralixibat), an oral solution approved for treating cholestatic pruritus in Alagille syndrome patients aged one and older. The presentation is scheduled for January 11 at 1:30 p.m. ET. Mirum will also host a fireside chat at the H.C. Wainwright Virtual BIOCONNECT 2022 Conference. Further information can be found on their website.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present at the annual J.P. Morgan Healthcare Conference taking place virtually January 10-13, 2022.

Chris Peetz, Mirum’s president and chief executive officer, will provide an overview of Mirum’s strategy and ongoing development program, as well as a commercial update for LIVMARLI™ (maralixibat) oral solution. Mr. Peetz and members of Mirum’s leadership team will be available for one-on-one meetings during the conference.

Presentation and Q&A Session

Date: Tuesday, January 11, 2022
Time: 1:30 – 2:10 p.m. ET

A live audio webcast and archive of Mirum’s presentation along with accompanying slides will be available in the Investors & Media section of the company’s website.

Additionally, the company will participate in a fireside chat at the upcoming H.C. Wainwright Virtual BIOCONNECT 2022 Conference. A webcast of the presentation will be accessible from the Investors & Media section of Mirum’s website beginning January 10, 2022, at 7:00 a.m. ET.

Visit the Investors and Media section of Mirum’s corporate website for additional information.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI™ (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome.

Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.

Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.

To augment its pipeline in cholestatic liver disease, Mirum has acquired the exclusive option to develop and commercialize gene therapy programs VTX-803 and VTX-802 for PFIC3 and PFIC2, respectively, from Vivet Therapeutics SAS, following preclinical evaluation and investigational new drug-enabling studies.

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005425/en/

Mirum Contacts:

Investors:

Ian Clements, Ph.D.

ir@mirumpharma.com

Sam Martin

Argot Partners

ir@mirumpharma.com

Media:

Erin Murphy

media@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

When will Mirum Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

Mirum Pharmaceuticals will present at the J.P. Morgan Healthcare Conference from January 10-13, 2022, with their presentation on January 11 at 1:30 p.m. ET.

Who is presenting for Mirum Pharmaceuticals at the conference?

Chris Peetz, the president and CEO of Mirum Pharmaceuticals, will present the company's strategy and updates.

What is LIVMARLI and its significance for Mirum Pharmaceuticals?

LIVMARLI™ (maralixibat) is an oral solution approved by Mirum for treating cholestatic pruritus in patients with Alagille syndrome aged one and older.

Is there a webcast available for Mirum's presentation?

Yes, a live audio webcast of Mirum's presentation will be available on their website.

What other conference will Mirum Pharmaceuticals participate in?

Mirum Pharmaceuticals will also participate in the H.C. Wainwright Virtual BIOCONNECT 2022 Conference.